Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin

American Journal of Physiology - Endocrinology and Metabolism

Volumn 285, Issue 1 48-1, 2003, Pages

  Dimaraki, Eleni V ^a   Jaffe, Craig A ^a,b   Bowers, Cyril Y ^c   Marbach, Peter ^d   Barkan, Ariel L ^a,b,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Diurnal rhythm; Ghrelin; Octreotide; Pulsatility; Somatotropin; Somatotropin releasing hormone

Indexed keywords

GHRELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; SODIUM CHLORIDE; SOMATOSTATIN;

ADULT; ARTICLE; BODY MASS; CIRCADIAN RHYTHM; CONTROLLED STUDY; GROWTH HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; PULSE RATE; SEX DIFFERENCE;

EID: 0037663825     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00334.2002     Document Type: Article

References (46)

1. Begley DJ. The interaction of some centrally active drugs with the blood-brain barrier and circumventricular organs. Prog Brain Res 91: 163-169, 1992.
2. Bermann M, Jaffe CA, Tsai W, DeMott-Friberg R, and Barkan AL. Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I. Involvement of hypothalamic somatostatin. J Clin Invest 94: 138-145, 1994.
3. Broglio F, Koetsveld Pv P, Benso A, Gottero C, Prodam F, Papotti M, Muccioli G, Gauna C, Hofland L, Deghenghi R, Arvat E, Van Der Lely AJ, and Ghigo E. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab 87: 4829-4832, 2002.
4. Clark RG, Carlsson LM, Rafferty B, and Robinson IC. The rebound release of growth hormone (GH) following somatostatin infusion in rats involves hypothalamic GH-releasing factor release. J Endocrinol 119: 397-404, 1988.
5. Di Vito L, Broglio F, Benso A, Gottero C, Prodam F, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Ghigo E, and Arvat E. The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clin Endocrinol (Oxf) 56: 643-648, 2002.
6. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Pan W, Brown MB, and Barkan AL. Analysis of pulsatile hormone secretion: Relative importance of biological versus technical variability. Ann. Mtg. Endocr. Soc. 82nd, Toronto 2000, p. A2015.
7. Dimaraki EV, Jaffe CA, Demott-Friberg R, Russell-Aulet M, Bowers CY, Marbach P, and Barkan AL. Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator. Am J Physiol Endocrinol Metab 280: E489-E495, 2001.
8. Frohman LA, Downs TR, Clarke IJ, and Thomas GB. Measurement of growth hormone-releasing hormone and somatostatin in hypothalamic-portal plasma of unanesthetized sheep. J Clin Invest 86: 17-24, 1990.
9. Ghigo E, Arvat E, Muccioli G, and Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol 136: 445-460, 1997.
10. Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, and Muller EE. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans. J Clin Endocrinol Metab 84: 285-290, 1999.
11. Giustina A and Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19: 717-797, 1998.
12. Gondo RG, Aguiar-Oliveira MH, Hayashida CY, Toledo SP, Abelin N, Levine MA, Bowers CY, Souza AH, Pereira RM, Santos NL, and Salvatori R. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. J Clin Endocrinol Metab 86: 3279-3283, 2001.
13. Jaffe CA, DeMott-Friberg R, and Barkan AL. Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. J Clin Invest 97: 934-940, 1996.
14. Jaffe CA, Friberg RD, and Barkan AL. Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest 92: 695-701, 1993.
15. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, and Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 77: 1641-1647, 1993.
16. Jaffe CA, Ocampo-Lim B, Guo W, Krueger K, Sugahara I, DeMott-Friberg R, Bermann M, and Barkan AL. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. J Clin Invest 102: 153-164, 1998.
17. Jaffe CA, Turgeon DK, Friberg RD, Watkins PB, and Barkan AL. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin - a clinical research center study. J Clin Endocrinol Metab 80: 3321-3326, 1995.
18. Katakami H, Hashida S, Usui T, and Matsukura S. Role of endogenous ghrelin in the control of GH secretion in conscious rats. Ann. Mtg. Endocr. Soc. 84th San Francisco 2002, p. P2-P110.
19. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, and Kangawa K. Ghrelin is a growth hormone-releasing acylated peptide from stomach. Nature 402: 656-660, 1999.
20. Kraicer J, Cowan JS, Sheppard MS, Lussier B, and Moor BC. Effect of somatostatin withdrawal and growth hormone (GH)-releasing factor on GH release in vitro: amount available for release after disinhibition. Endocrinology 119: 2047-2051, 1986.
21. Low MJ, Otero-Corchon V, Parlow AF, Ramirez JL, Kumar U, Patel YC, and Rubinstein M. Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth. J Clin Invest 107: 1571-1580, 2001.
22. Magnan E, Cataldi M, Guillaume V, Conte-Devolx B, Graziani N, Figaroli JC, Thomas F, Chihara K, and Oliver C. Acute changes in growth hormone-releasing hormone secretion after injection of BIM 23014, a long acting somatostatin analog, in rams. Life Sci 51: 831-838, 1992.
23. Magnan E, Mazzocchi L, Cataldi M, Guillaume V, Dutour A, Dadoun F, Le Bouc Y, Sauze N, Renard M, Conte-Devolx B, and Oliver C. Effect of actively immunizing sheep against growth hormone-releasing hormone or somatostatin on spontaneous pulsatile and neostigmine-induced growth hormone secretion. J Endocrinol 144: 83-90, 1995.
24. Maheshwari HG, Pezzoli SS, Rahim A, Shalet SM, Thorner MO, and Baumann G. Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance. Am J Physiol Endocrinol Metab 282: E943-E951, 2002.
25. Marbach P, Neufeld M, and Pless J. Clinical applications of somatostatin analogs. Adv Exp Med Biol 188: 339-353, 1985.
26. Miki N, Ono M, and Shizume K. Withdrawal of endogenous somatostatin induces secretion of growth hormone-releasing factor in rats. J Endocrinol 117: 245-252, 1988.
27. Nakamura S, Mizuno M, Katakami H, Gore AC, and Terasawa E. Aging-related changes in in vivo release of growth hormone-releasing hormone and somatostatin from the stalkmedian eminence in female rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab 88: 827-833, 2003.
28. Norrelund H, Hansen TK, Orskov H, Hosoda H, Kojima M, Kangawa K, Weeke J, Moller N, Christiansen JS, and Jorgensen JO. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 57: 539-546, 2002.
29. Ocampo-Lim B, Guo W, DeMott-Friberg R, Barkan AL, and Jaffe CA. Nocturnal growth hormone (GH) secretion is eliminated by infusion of GH-releasing hormone antagonist. J Clin Endocrinol Metab 81: 4396-4399, 1996.
30. Painson JC and Tannenbaum GS. Sexual dimorphism of somatostatin and growth hormone-releasing factor signaling in the control of pulsatile growth hormone secretion in the rat. Endocrinology 128: 2858-2866, 1991.
31. Plotsky PM and Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion in the hypophysial-portal circulation of the rat. Science 230: 461-463, 1985.
32. Reubi JC and Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 59: 1148-1151, 1984.
33. Roelfsema F, Biermasz NR, Veldman RG, Veldhuis JD, Frolich M, Stokvis-Brantsma WH, and Wit JM. Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses. J Clin Endocrinol Metab 86: 2459-2464, 2001.
34. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, and Matsukura S. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87: 240-244, 2002.
35. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, and Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99: 789-798, 1997.
36. Stachura ME. Interaction of somatostatin inhibition and dibutyryl cyclic AMP or potassium stimulation of growth hormone release from perifused rat pituitaries. Endocrinology 101: 1044-1053, 1977.
37. Tannenbaum GS and Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology 115: 1952-1957, 1984.
38. Thomas CB, Groot K, and Arimura A. Antiserum to rat growth hormone (GH)-releasing factor suppresses but does not abolish antisomatostatin-induced GH release in the rat. Endocrinology 116: 2174-2178, 1985.
39. Thomas GB, Cummins JT, Francis H, Sudbury AW, McCloud PI, and Clarke IJ. Effect of restricted feeding on the relationship between hypophysial portal concentrations of growth hormone (GH)-releasing factor and somatostatin, and jugular concentrations of GH in ovariectomized ewes. Endocrinology 128: 1151-1158, 1991.
40. Tulipano G, Soldi D, Bagnasco M, Culler MD, Taylor JE, Cocchi D, and Giustina A. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143: 1218-1224, 2002.
41. Van Kessel AG and Laarveld B. Acute or chronic immunoneutralzation of somatostatin does not affect growth hormone or thyroid hormone secretion in sheep. J Endocrinol 136: 261-269, 1993.
42. Vance ML, Kaiser DL, Evans WS, Furlanetto R, Vale W, Rivier J, and Thorner MO. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). J Clin Invest 75: 1584-1590, 1985.
43. Veldhuis JD and Johnson ML. Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection. Am J Physiol Endocrinol Metab 250: E486-E493, 1986.
44. Veldhuis JD and Johnson ML. Deconvolution analysis of hormone data. Methods Enzymol 210: 539-575, 1992.
45. Webb CB, Vance ML, Thorner MO, Perisutti G, Thominet J, Rivier J, Vale W, and Frohman LA. Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. J Clin Invest 74: 96-103, 1984.
46. Williams TC, Kelijman M, Crelin WC, Downs TR, and Frohman LA. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. J Clin Endocrinol Metab 66: 39-45, 1988.